PGNY
Strong BuyFull HouseAPPROVEProgyny, Inc. · Healthcare · United States · $2.0B · Avg Vol: $32M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Passes all quantitative thresholds and demonstrates positive fundamental momentum via EPS revisions (3.2%) and active buyback management. Operates with a defensible niche in the healthcare sector.
ABOUT PROGYNY, INC.
Read
Progyny, Inc. is a leading fertility and family building benefits management company, providing comprehensive and inclusive fertility solutions to large self-insured employers. The company's unique 'Smart Cycle' model and high success rates offer a differentiated value proposition, driving strong employer adoption and member satisfaction. This innovative approach and clinical expertise create a significant competitive moat in the niche but growing market for fertility benefits.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 786.9M | 1.1B | 1.2B | 1.3B | 17.9% | 1.3B | 1.4B | 1.5B | 8.3% |
| EPS | 0.33 | 0.65 | 0.59 | 0.68 | 27.3% | 0.92 | 0.75 | 0.83 | 10.8% |
| Shares | 93.3M | 96.3M | 85.3M | 83.4M | -10.6% | 76.7M | — | — | — |
| Debt | 7.7M | 19.4M | 19.3M | 27.7M | 53.2% | 22.5M | — | — | — |
| Equity | 377.0M | 553.4M | 422.1M | 516.0M | 11.0% | — | — | — | — |
| Op CF | 80.4M | 188.8M | 179.1M | 210.2M | 37.8% | 201.2M | — | — | — |
| Inv CF | -43.9M | -200.5M | 195.8M | -159.0M | — | — | — | — | — |
| Fin CF | -7.9M | -11.1M | -309.9M | -99.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PGNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PGNY | Progyny, Inc.(you) | $2.0B | 98 | Strong Buy |
| CLOV | Clover Health Investments, Corp. | $2.2B | 79 | Buy |
| OSCR | Oscar Health, Inc. | $9.4B | 98 | Strong Buy |
| ALHC | Alignment Healthcare, Inc. | $2.8B | 59 | Hold |
| MOH | Molina Healthcare, Inc. | $10.4B | 71 | Buy |
| CNC | Centene Corporation | $32.0B | 93 | Strong Buy |
| HUM | Humana Inc. | $46.3B | 89 | Strong Buy |
| CI | The Cigna Group | $73.7B | 92 | Strong Buy |
| ELV | Elevance Health, Inc. | $85.5B | 90 | Strong Buy |
| CVS | CVS Health Corporation | $119.0B | 93 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.